Nephros Announces Preliminary Third Quarter Revenues of $2.1 Million

Announces Preliminary Third Quarter Revenues of $2.1 Million

ORANGE, NJ, October 6, 2020 - Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high

performance water purification products and pathogen detection systems to the medical and commercial markets, today announced

preliminary financial results for the quarter ended September 30, 2020.

revenues for the quarter are expected to be $2.1 million, a sequential increase of approximately 34% compared to the prior quarter

ended June 30, 2020, and a decrease of approximately 32% compared to the quarter ended September 30, 2019. Nephros ended the quarter

with approximately $5.2 million in cash on a consolidated basis.

COVID-19 pandemic continues to impact our revenues, particularly in terms of new customer acquisition, emergency outbreak response,

and hotel and restaurant sales," said Andy Astor, President and CEO of Nephros. "However, we are pleased that recurring

revenues from existing customers are meeting expectations and that our customer retention rates remain excellent. These metrics

indicate to us the underlying strength of our business."

Astor continued, "We are also making excellent progress in several important areas, including new opportunities in the food

and beverage market, the development of new pathogen detection products, and completing our second-generation HDF product. We

expect to have more to say about each of these areas in the remaining months of 2020."

is a commercial-stage company that develops and markets high performance water purification products and pathogen detection systems

for medical and commercial markets.

ultrafilters are used in hospitals, medical clinics, and commercial facilities to retain bacteria and viruses from water, providing

barriers that aid in infection control for showers, sinks, and ice machines. Nephros ultrafilters are also used in dialysis centers

to aid in the removal of endotoxins and other biological contaminants from water and bicarbonate concentrate in hemodialysis machines.

pathogen detection systems, including the PluraPath , SequaPath , and DialyPath systems, provide

data on water-borne biological content to medical and water quality professionals. Our products integrate Nephros ultrafilters

with quantitative polymerase chain reaction (qPCR) technology to deliver actionable water pathogen information in real time.

commercial filters, including AETHER brand filters, improve the taste and odor of water, and reduce scale build-up in downstream

equipment. Nephros and AETHER products are used in the health care, food service, hospitality, and convenience store markets.

more information about Nephros, please visit its website at www.nephros.com.

release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements

regarding Nephros's expected revenue for the quarter ended September 30, 2020, the anticipated impact of the coronavirus

pandemic, expected demand for Nephros' products, including its new pathogen detection products, and other statements that

are not historical facts, including statements that may be accompanied by the words "intends," "may,"

"will," "plans," "expects," "anticipates," "projects," "predicts,"

"estimates," "aims," "believes," "hopes," "potential" or similar words.

Actual results could differ materially from those described in these forward-looking statements due to certain factors, including

changes in business, competitive and economic conditions, particularly the continued impact of the COVID-19 pandemic on the U.S.

economy, and the availability of financing or other capital when needed. These and other risks and uncertainties are detailed

in Nephros's reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for

the year ended December 31, 2019. Nephros does not undertake any responsibility to update the forward-looking statements in this